Illumina, Inc.
Illumina Announces Fiscal Year 2025 Guidance and Cost Reductions Amid China Export Ban
Summary
Illumina, Inc. announced on March 10, 2025, that it respects the China Ministry of Commerce's decision to prohibit the export of sequencing instruments into China. The company expects its Core Illumina fiscal 2025 non-GAAP diluted EPS to be approximately $4.50 and is implementing a cost reduction program of about $100 million for fiscal 2025 to mitigate the potential impact of reduced revenue from its Greater China business.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement